Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy.
Harbeck N, Kates R, Schinköthe T, Schumacher J, Wuerstlein R, Degenhardt T, Lüftner D, Räth P, Hoffmann O, Lorenz R, Decker T, Reinisch M, Göhler T, Staib P, Gluz O, Fasching PA, Schmidt M; AGO-B, WSG PreCycle investigators.
Evaluating the ability of an artificial-intelligence cloud-based platform
designed to provide information prior to locoregional therapy for breast cancer in improving patient's satisfaction with therapy: The CINDERELLA trial.
Kaidar-Person O, Antunes M, Cardoso JS, Ciani O, Cruz H, Di Micco R,
Gentilini OD, Gonçalves T, Gouveia P, Heil J, Kabata P, Lopes D, Martinho M, Martins H, Mavioso C, Mika M, Montenegro H, Oliveira HP, Pfob A, Rotmensz N, Schinköthe T, Silva G, Tarricone R, Cardoso MJ; CINDERELLA Consortium.
Significantly longer time to deterioration of quality of life due to CaNKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N, Fasching PA, Wuerstlein R, Degenhardt T, Lüftner D, Kates RE, Schumacher J, Räth P, Hoffmann O, Lorenz R, Decker T, Reinisch M, Göhler T, Staib P, Gluz O, Schinköthe T, Schmidt M; AGO-B WSG PreCycle investigators.
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
Degenhardt T, Fasching PA, Lüftner D, Müller V, Thomssen C, Schem C, Witzel I, Decker T, Tesch H, Kümmel S, Uleer C, Wuerstlein R, Hoffmann O, Warm M, Marschner N, Schinköthe T, Kates RE, Schumacher J, Otremba B, Zaiss M, Harbeck N, Schmidt M; PreCycle Investigators.
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor- Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
Gluz O, Nitz UA, Christgen M, Kuemmel S, Holtschmidt J, Schumacher J, Hartkopf A, Potenberg J, Lüedtke-Heckenkamp K, Just M, Schem C, von Schumann R, Kolberg-Liedtke C, Eulenburg CZ, Schinköthe T, Graeser M, Wuerstlein R, Kates RE, Kreipe HH, Harbeck N.
Chemotherapy-induced peripheral neuropathy (CIPN) prevention trial evaluating the efficacy of hand-cooling and compression in patients undergoing taxan-based (neo-)adjuvant chemotherapy for primary breast cancer: First results of the prospective, randomized POLAR trial
L. Michel, P. Romar, M. Feisst, D. Hamberger, D. Schwarz, E. Kurre, E. Klein, M.O. Breckwoldt, A. Priester, M. Weiler, K. Smetanay, C. Fremd, D. Jäger, M. Bendszus, F. Marmé, A. Schneeweiss
Should routine risk reduction procedures for the prevention and control of pandemics become a standard in all oncological outpatient clinics? The prospective COVID-19 cohort study: protect-CoV.
Fey T, Erickson N, Stahler A, Muenchhoff M, Keppler OT, Ruehlmann K, Krauss-Pfeiffer G, Steinberg H, Graf A, Krebs S, Blum H, Khatamzas E, Seynstahl S, Casuscelli J, Markwardt D, Forstpointner R, Schinköthe T, von Bergwelt-Baildon M, Heinemann V.
Patient-reported outcome measures obtained via E-Health tools ease the assessment burden and encourage patient participation in cancer care (PaCC Study).
Erickson N, Schinkoethe T, Eckhardt C, Storck L, Joos A, Liu L, Ballmer PE, Mumm F, Fey T, Heinemann V.